The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Alnylam Pharmaceuticals

  • ALNY
  • NASDAQ
  • Consumer Products
  • Latest 53.55
  • Currency US$
  • Change -1.99
  • Percent Change -3.583 %
  • Volume 453,002
  • Thu Jul 31, 2014 01:43 PM EDT NASDAQ data delayed 15 minutes.
  • Open 54.77
  • Previous Close 55.54
  • High 55.23
  • Low 52.43
  • Bidx1 53.43
  • Askx1 53.58
  • 52-week High01/13 112.57
  • 52-week Low07/30 44.76
  • Beta 2.392
  • Market Cap 3,422.92M
  • EPS -1.67
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $36,800,000
  • Earnings $-331,160,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow n/a
  • Cash n/a
  • Current Ratio n/a

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $1,080,290,000
  • Liabilities $125,320,000
  • Liabilities-to-Equity Ratio 0.13

Price Ratios

  • Price to Sales 92.84
  • Price to Book 3.58
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 8 $-1.18 Aug 14 $-0.54
Surprises May 8 -66.95% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 31, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Related Securities
Symbol Type Latest % Chg

Officers

  • John M. Maraganore Director & Chief Executive Off
  • Michael P. Mason Vice President of Finance & Tr
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

300 THIRD STREET
CAMBRIDGE, MA
02142

Phone: (617)-551-8200
Fax: (617)-5518101

investors@alnylam.com
www.alnylam.com

Ideas & Discussion

Live Discussion of ALNY on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.